COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

DBT and Escitalopram in Borderline Personality Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00255554
Recruitment Status : Unknown
Verified November 2005 by Bronx VA Medical Center.
Recruitment status was:  Recruiting
First Posted : November 21, 2005
Last Update Posted : November 21, 2005
Information provided by:
Bronx VA Medical Center

Brief Summary:
Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Condition or disease Intervention/treatment Phase
Borderline Personality Disorder Behavioral: Dialectical Behavioral Therapy Drug: Escitalopram Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Measures of impulsivity, aggression, affective impulsivity, immediate and delayed memory, and cognitive processing at baseline, 6 months and 9 months

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: Is a male or female between 18 and 60 who meets criteria for Borderline Personality Disorder and has been off psychotropic medications for at least 2 weeks (6 weeks for fluoxetine).


Exclusion Criteria: Meets criteria for Schizophrenia, Bipolar Disorder, Mental Retardation, current or recent Substance Dependence or a current Major Depressive Episode. Subjects also should not currently be in individual psychotherapy. (Case management and work therapy programs are allowed.)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00255554

Layout table for location contacts
Contact: Emily Hart 212-241-0441

Layout table for location information
United States, New York
Bronx VA Medical Center Recruiting
Bronx, New York, United States, 10029
Sponsors and Collaborators
Bronx VA Medical Center
Layout table for investigator information
Principal Investigator: Marianne Goodman, MD Bronx VA Medical Center/Mount Sinai School of Medicine

Layout table for additonal information Identifier: NCT00255554    
Other Study ID Numbers: 3277-03-0027
First Posted: November 21, 2005    Key Record Dates
Last Update Posted: November 21, 2005
Last Verified: November 2005
Keywords provided by Bronx VA Medical Center:
Borderline Personality Disorder
Dialectical Behavior Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Personality Disorders
Borderline Personality Disorder
Mental Disorders
Pathologic Processes
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs